MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-11-2025
Evolent Health Balance Sheet 2011-2026 | EVH
Annual Balance Sheet Evolent Health
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
232 M | -43.5 M | -90.9 M | 194 M | -6.46 M | -117 M | 30.1 M | -146 M | - | -67.9 M | - | - |
Long Term Debt |
413 M | 216 M | 263 M | 294 M | 221 M | 121 M | 120 M | - | - | - | - | - |
Long Term Debt Current |
7.12 M | 7.07 M | 7.36 M | 6.27 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 376 M | 264 M | 134 M | 156 M | 21.4 M | 40.3 M | 41.6 M | - | - |
Total Current Liabilities |
433 M | 445 M | 402 M | 193 M | 269 M | 133 M | 132 M | 59.5 M | - | - | - | - |
Total Liabilities |
958 M | 726 M | 751 M | 569 M | 533 M | 266 M | 288 M | 80.9 M | 40.3 M | 70.9 M | - | - |
Deferred Revenue |
5.76 M | 11.9 M | 14.3 M | 19.8 M | 20.6 M | 24.8 M | 20.5 M | 14.8 M | - | 16.4 M | - | - |
Retained Earnings |
-606 M | -627 M | -589 M | -252 M | 50 M | 86 M | 147 M | 307 M | -25.8 M | - | - | - |
Total Assets |
1.82 B | 1.42 B | 1.37 B | 1.5 B | 1.72 B | 1.31 B | 1.2 B | 1.02 B | 38.3 M | 102 M | - | - |
Cash and Cash Equivalents |
188 M | 266 M | 362 M | 101 M | 228 M | 238 M | 135 M | 146 M | - | - | - | - |
Book Value |
859 M | 694 M | 620 M | 929 M | 1.19 B | 1.05 B | 912 M | 935 M | -2.07 M | 31 M | - | - |
Total Shareholders Equity |
859 M | 694 M | 620 M | 922 M | 1.14 B | 1.01 B | 703 M | 649 M | -2.07 M | 13.3 M | - | - |
All numbers in USD currency
Quarterly Balance Sheet Evolent Health
| 2025-Q2 | 2024-Q2 | 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
648 M | - | 600 M | - | 412 M | - | 283 M | 216 M | 211 M | 207 M | 202 M | 263 M | 263 M | 263 M | 297 M | 294 M | 228 M | 294 M | 294 M | 221 M | 221 M | 221 M | 221 M | 121 M | 121 M | 121 M | 121 M | 120 M | 120 M | 120 M | 120 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.34 B | - | 1.4 B | - | 903 M | - | 728 M | 726 M | 646 M | 679 M | 688 M | 752 M | 752 M | 752 M | 604 M | 569 M | 569 M | 569 M | 569 M | 533 M | 533 M | 533 M | 533 M | 266 M | 266 M | 266 M | 266 M | 288 M | 288 M | 288 M | 288 M | 80.9 M | 80.9 M | 80.9 M | 80.9 M | - | 1.07 M | 1.07 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
2.33 M | - | 5.76 M | - | 7.52 M | - | 13.3 M | 11.9 M | 13.8 M | 13.2 M | 13.4 M | 10.2 M | 10.2 M | 10.2 M | 17 M | 19.8 M | 19.8 M | 19.8 M | 19.8 M | 20.6 M | 20.6 M | 20.6 M | 33.3 M | 24.8 M | 26.1 M | 27.8 M | 25.5 M | 20.5 M | 20.5 M | 20.5 M | 20.5 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-865 M | - | -686 M | - | -595 M | - | -592 M | -627 M | -621 M | -608 M | -599 M | -589 M | -589 M | -589 M | -334 M | -252 M | -252 M | -252 M | -252 M | 50 M | 50 M | 50 M | 50 M | 86 M | 86 M | 86 M | 86 M | 147 M | 147 M | 147 M | 147 M | 307 M | 307 M | 307 M | 307 M | -25.8 M | -25.8 M | -25.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
2.46 B | - | 2.67 B | - | 1.76 B | - | 1.34 B | 1.42 B | 1.25 B | 1.29 B | 1.31 B | 1.37 B | 1.37 B | 1.37 B | 1.45 B | 1.5 B | 1.5 B | 1.5 B | 1.5 B | 1.72 B | 1.72 B | 1.72 B | 1.72 B | 1.31 B | 1.31 B | 1.31 B | 1.31 B | 1.2 B | 1.2 B | 1.2 B | 1.2 B | 1.02 B | 1.02 B | 1.02 B | 1.02 B | 37.2 M | 38.3 M | 38.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
151 M | 101 M | 185 M | - | 157 M | - | 210 M | 266 M | 282 M | 207 M | 236 M | 319 M | 319 M | 319 M | 67.9 M | 101 M | 101 M | 101 M | 101 M | 228 M | 228 M | 228 M | 228 M | 238 M | 238 M | 238 M | 238 M | 135 M | 135 M | 135 M | 135 M | 146 M | 146 M | 146 M | 146 M | - | - | - | - | - | - | - | - | 5.25 M | - | - | - | - | - | - | - |
Book Value |
1.12 B | - | 1.27 B | - | 856 M | - | 611 M | 694 M | 607 M | 614 M | 617 M | 620 M | 620 M | 620 M | 847 M | 929 M | 929 M | 929 M | 929 M | 1.19 B | 1.19 B | 1.19 B | 1.19 B | 1.05 B | 1.05 B | 1.05 B | 1.05 B | 912 M | 912 M | 912 M | 912 M | 935 M | 935 M | 935 M | 935 M | 37.2 M | 37.2 M | 37.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
896 M | 1.05 B | 1.1 B | - | 856 M | - | 611 M | 694 M | 607 M | 614 M | 617 M | 620 M | 620 M | 620 M | 847 M | 922 M | 922 M | 922 M | 922 M | 1.14 B | 1.14 B | 1.14 B | 1.14 B | 1.01 B | 1.01 B | 1.01 B | 1.01 B | 703 M | 703 M | 703 M | 703 M | 649 M | 649 M | 649 M | 649 M | -2.07 M | -2.07 M | -2.07 M | - | 13.3 M | - | - | - | 5.2 M | - | - | - | - | - | - | - |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Evolent Health, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Health information services
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Accolade
ACCD
|
- | 0.29 % | $ 206 M |  USA |
 |
Change Healthcare
CHNG
|
- | - | $ 9.03 B | USA |
 |
Cerner Corporation
CERN
|
- | - | $ 27.9 B | USA |
 |
American Well Corporation
AMWL
|
$ 5.63 | -2.26 % | $ 90.3 M | USA |
 |
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | USA |
 |
Covetrus
CVET
|
- | - | $ 2.94 B | USA |
 |
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | USA |
 |
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | USA |
 |
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | USA |
 |
HealthStream
HSTM
|
$ 21.23 | 1.24 % | $ 645 M | USA |
 |
iCAD
ICAD
|
- | - | $ 102 M | USA |
 |
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | USA |
 |
Omnicell
OMCL
|
$ 34.94 | 1.39 % | $ 1.61 B | USA |
 |
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | USA |
 |
OptimizeRx Corporation
OPRX
|
$ 7.18 | 5.9 % | $ 123 M | USA |
 |
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | USA |
 |
Phreesia
PHR
|
$ 11.28 | - | $ 615 M | USA |
 |
Premier
PINC
|
- | - | $ 2.33 B | USA |
 |
GoodRx Holdings
GDRX
|
$ 2.06 | 0.98 % | $ 795 M | USA |
 |
Schrödinger
SDGR
|
$ 11.4 | -1.47 % | $ 837 M | USA |
 |
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | USA |
 |
R1 RCM
RCM
|
- | - | $ 3.81 B | USA |
 |
Akerna Corp.
KERN
|
- | - | $ 161 M | USA |
 |
Zhongchao
ZCMD
|
$ 1.8 | -0.55 % | $ 9.37 M |  China |
 |
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | USA |
 |
Teladoc Health
TDOC
|
$ 5.57 | 2.77 % | $ 982 M | USA |
 |
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | USA |
 |
10x Genomics
TXG
|
$ 20.91 | 5.55 % | $ 2.45 B | USA |
 |
Health Catalyst
HCAT
|
$ 1.1 | 0.46 % | $ 76.9 M | USA |
 |
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | USA |
 |
HealthEquity
HQY
|
$ 82.47 | 0.45 % | $ 7.1 B | USA |
 |
SCWorx Corp.
WORX
|
$ 0.13 | 1.5 % | $ 190 K | USA |
 |
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | USA |
 |
Progyny
PGNY
|
$ 17.75 | -1.66 % | $ 1.52 B | USA |
 |
So-Young International
SY
|
$ 3.19 | 9.62 % | $ 253 M | China |
 |
Veeva Systems
VEEV
|
$ 178.11 | -0.56 % | $ 29.2 B | USA |